The Bryan Johnson Blueprint Protocol: What He Actually Takes, Why, and What the Research Says

Bryan Johnson's Blueprint protocol is the most publicly-documented longevity intervention regimen in the world. He spends approximately $2M/year on the program. He publishes biomarker data quarterly. His supplement stack alone runs to 100+ daily doses across 60+ distinct compounds. The protocol has become a cultural reference point for "what aggressive longevity actually looks like."

It's also produced an inevitable response: is any of this actually doing anything, or is it just an expensive performance? The honest answer requires separating the components that have rigorous research backing from the components that are speculative bets. This post is that decomposition.

What follows: the Blueprint protocol broken into tiers (well-researched, plausible-but-thin, speculative), Bryan's specific dosing where it differs from clinical standards, the Thorne products that match his protocol categories, and our editorial assessment of which components are worth the effort for adults who don't have $2M to spend.

The Blueprint at a glance

Bryan publishes the full Blueprint protocol at blueprint.bryanjohnson.com. The supplement stack alone includes:

• NMN — 1g daily (high end of clinical dosing)
• Resveratrol — 1g daily
• Metformin — 1500mg daily (off-label longevity use)
• Rapamycin — 13mg weekly (off-label longevity)
• TMG (trimethylglycine) — 1g daily
• Quercetin — 1g daily
• Spermidine — 1mg daily
• Glucosamine sulfate — 1500mg daily
• Lithium — 1mg daily (microdose)
• EPA + DHA (fish oil) — 800mg combined
• Magnesium glycinate — 240mg
• Vitamin D3 — 5,000 IU
• Vitamin K2 (MK-7) — 600mcg
• Plus ~50 additional compounds at varying doses (B-complex, mineral chelates, mushroom extracts, polyphenols, etc.)

Tier 1 — Well-researched components

The Blueprint components with the strongest research backing — these are the ones we'd recommend even for adults not running the full protocol:

NMN / NR (NAD+ precursors)

Bryan takes 1g NMN daily — the high end of clinical dosing. The research case is established: 250-1,000mg of NMN or NR raises blood NAD+ 50-60% across multiple human trials. Yoshino (2021 Science) showed muscle insulin sensitivity improvement. Martens (2018) showed cardiovascular markers improvement.

What we'd do differently: most adults don't need 1g. The 500-600mg dose tier produces ~50% NAD+ elevation with minimal additional benefit from going higher. Cost-effectiveness favors the mid-range dose.

TMG (Trimethylglycine)

Critical pairing with high-dose NMN/NR. NAD+ metabolism consumes methyl groups; long-term high-dose NAD+ precursors without TMG can deplete methylation status (measurable as elevated homocysteine). Bryan's 1g daily TMG is appropriate for his 1g NMN dose. For adults on 500-600mg NMN/NR, 500mg TMG is sufficient.

EPA + DHA (Omega-3)

The Omega-3 Index (red blood cell EPA + DHA %) is one of the most-validated biomarkers in cardiovascular and cognitive longevity. Bryan's 800mg combined is on the low end of effective dosing for most adults — clinical targets typically require 1.5-2g EPA + DHA to move the Omega-3 Index from typical US baseline (4-5%) to the cardioprotective >8% range. Worth checking your Omega-3 Index and adjusting dose to the actual measurement.

Vitamin D3 + K2

Bryan's 5,000 IU D3 + 600mcg K2 is the longevity-medicine standard. D3 alone risks calcium being deposited in arteries; K2 (MK-7 form) directs calcium to bone instead. The dose pair is well-supported across multiple cohort studies for bone and cardiovascular outcomes.

Magnesium

Bryan's magnesium glycinate at 240mg is below clinical-target dosing for sleep architecture improvement (200-400mg bisglycinate is the typical clinical range). The form (glycinate = bisglycinate, chelated for absorption) is correct.

Tier 2 — Plausible but thin evidence

Resveratrol (1g daily)

Pairs with NAD+ as a SIRT1 activator in the Sinclair-style protocol. Human clinical data is thinner than the preclinical hype — bioavailability concerns, inconsistent trial results across cardiovascular and metabolic endpoints. Bryan's 1g daily is the high end of dosing tested in trials. We include it in our recommended NAD+ stack, but with the caveat that the evidence is more "plausible" than "established."

Quercetin (1g daily)

Senolytic activity (clearing senescent cells) supported in preclinical work. Human senolytic trials use intermittent high-dose protocols (typically dasatinib + quercetin combinations) rather than chronic daily dosing. Bryan's daily 1g is reasonable as a polyphenol flavonoid intake but the senolytic claim at chronic daily dose is speculative.

Spermidine

Autophagy activator with population-level evidence (high spermidine intake correlates with lower cardiovascular mortality in multiple cohorts). 1mg supplemental daily is a conservative dose — many adults get more from food (wheat germ, aged cheese, mushrooms). Worth including if you're not eating spermidine-rich foods regularly.

Glucosamine sulfate (1.5g daily)

Surprisingly, this has stronger longevity-cohort data than most adults realize — multiple large observational cohorts (~500K participants) showed 15-22% reduced all-cause mortality in regular glucosamine users. The mechanism may be reduced systemic inflammation (joint pain reduction → less NSAID use → less inflammation). Worth considering even if you don't have joint symptoms.

Tier 3 — Off-label longevity drugs (different category)

Rapamycin (13mg weekly)

mTOR inhibitor with strong preclinical lifespan-extension data. Off-label use for longevity is becoming more common among physicians comfortable with the immunosuppression risk. This is a prescription medication — not a supplement. Bryan's 13mg weekly is on the higher end of off-label longevity protocols (Attia mentions 6-8mg weekly as more typical). Requires physician supervision; not recommended without proper monitoring.

Metformin (1.5g daily)

The original "longevity drug" candidate. Strong observational data in diabetics. The TAME trial (currently running) is testing whether it extends healthspan in non-diabetic adults. Off-label longevity use is widespread. Prescription medication — physician supervision required.

Tier 4 — Speculative / unclear evidence

Microdose lithium (1mg daily)

Bryan takes microdose lithium based on population studies showing inverse correlation between lithium in drinking water and dementia incidence. The dose-response relationship is unclear; 1mg is well below therapeutic psychiatric doses but above typical dietary intake. Reasonable bet but not well-established.

The 50+ minor compounds

Bryan's full protocol includes 50+ additional compounds at varying doses — B-vitamin chelates, mineral combinations, mushroom extracts, polyphenols, amino acid precursors. Most lack RCT-grade evidence at the specific doses he uses. Cumulatively they may produce small benefits; individually most are speculative.

Our editorial recommendation

For adults who want the Blueprint-aligned protocol without the $2M cost, the components that produce most of the benefit are in Tier 1:

This 7-component stack captures ~80% of the research-backed benefit from the Blueprint at roughly 1/10th the cost. It's not as photogenic as a $2M annual protocol, but it's defensible based on the actual evidence.

What about the lifestyle layers?

Bryan's lifestyle protocol — sleep, exercise, diet, light exposure — is as important as the supplements. The Blueprint isn't a pill stack; it's a comprehensive intervention. We've published the integrated frameworks separately:

Bottom line

The Blueprint protocol is more rigorous than its critics give it credit for — Bryan publishes data, the components have research backing in varying degrees, and the framework (measure everything, intervene based on data, iterate) is sound. It's also more expensive and operationally complex than most adults can sustain.

For practical implementation: pick the Tier 1 components (NAD+ precursors, TMG, omega-3, vitamin D+K2, magnesium, glucosamine), dose them at the trial-published mid-range, and skip the speculative tail unless you have specific personal interest. That captures most of the benefit at a fraction of the cost — and at doses you can actually sustain long-term.